While over 90% of patients with cancer express interest in participating in a trial, less than 10% actually do. Dr. Parikh is leading a robust multi-year funded portfolio of work to develop and test AI tools to improve prescreening of patients, improve outcome and adverse event ascertainment, and generalize results to broad communities.
